EDRE
KPTI icon

Edmond de Rothschild (Europe)’s Karyopharm Therapeutics KPTI Stock Holding History

Edmond de Rothschild (Europe)’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-933
Closed -$381K – 270
2015
Q2 		$381K Buy
+933
New +$403K 0.12% 116

Other funds holding KPTI

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Edmond de Rothschild (Europe)'s KPTI Position: Q3 2015 in Review

Edmond de Rothschild (Europe) sold out of Karyopharm Therapeutics (KPTI) in Q3 2015, closing a stake of 933 shares — an estimated $381K sold.

Edmond de Rothschild (Europe) first reported a position in KPTI in Q2 2015 and held it in 1 quarter. The position peaked at $381K in Q2 2015. 89 funds tracked by Wall St. Rank hold KPTI as of Q3 2015.

  • Edmond de Rothschild (Europe) reported no remaining Karyopharm Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Edmond de Rothschild (Europe) sold 933 Karyopharm Therapeutics shares in Q3 2015, an estimated $381K.
  • Edmond de Rothschild (Europe) first reported a position in Karyopharm Therapeutics in Q2 2015 and held it in 1 quarter.
  • Edmond de Rothschild (Europe)'s Karyopharm Therapeutics position peaked at $381K in Q2 2015.
  • 89 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2015.

Based on Edmond de Rothschild (Europe)'s 13F filing for Q3 2015, filed 16 Nov 2015.